Searchable abstracts of presentations at key conferences in endocrinology

ea0011p158 | Clinical case reports | ECE2006

Plasma exchange for the prevention of severe thyrotoxic exacerbation following radioactive iodine therapy for Graves hyperthyroidism

Wee A , DeSilva V , Prentice MG

We present 2 patients who developed severe thyrotoxic exacerbation following radioiodine. The first treated by conventional antithyroid therapy, the second was plasma exchanged.Patient A aged 39 male with FT3=28.2 pmol/l (2.5–5.3) FT4=49.0 pmol/l (9.1–23.8) TSH=<0.01 mU/l (0.32–5.0),a large diffuse goitre, thyroid eye disease and asthmatic on inhaled ventolin. He received 3.5 years of carbimazole 40 mg and thyroxine 100 mcg. Thyroxine ...

ea0005p249 | Steroids | BES2003

Mutations in the HSD11B2 gene causing AME in the Oman population

Atterbury A , Draper N , Lavery G , Walker E , DeSilva V , Taylor N , Hala S , Rajendra N , Bappal B , Stewart P

Mutations in the HSD11B2 gene explain the syndrome of apparent mineralocorticoid excess (AME), which is characterised by severe hypokalaemic hypertension. Cortisol acts as a mineralocorticoid through failure of its inactivation to cortisone by 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2). Patients are diagnosed by a raised THF+allo-THF/THE ratio. To date, approximately 30 mutations have been described in HSD11B2. Recently, three apparently unrelated kindreds with A...